Effective July 5, 2017, the Molecular Genetics Laboratory will offer a TERT promoter mutation test.

**Clinical Indications for TERT Promoter Mutation Testing:**
*TERT* promoter mutation helps to refine prognosis in glioma and serves as a tumor marker in multiple cancer types.

Histologically low grade glioma harboring *TERT* promoter mutation, wild-type *IDH1/2*, and lacking 1p/19q deletion has a poor prognosis comparable to that of glioblastoma (grade 4).

**Specimen Requirements:**
This assay sequences genomic DNA extracted from paraffin-embedded tissue. Ten unstained slides from a block diagnostic for tumor should be submitted, along with an H&E stained slide marked by the pathologist to indicate the most tumor-rich region (at least 50% tumor cells required). After macrodissection and DNA extraction, the *TERT* promoter region is analyzed by Sanger sequencing. Results at positions -124C>T (also called C228T) and -146C>T (also called C250T) are interpreted by a pathologist.

**Reference:**

**Questions?** Call the UNC Molecular Genetics Lab at (984) 974-1825 or Dr. Margaret Gulley at (919) 843-4595. E-mail: margaret_gulley@med.unc.edu